Domo signs strategic collaboration agreement with AWS for AI solutions
Arturo Molina, MD, the Chief Medical (TASE:BLWV) Officer of Protagonist Therapeutics, Inc. (NASDAQ:PTGX), recently sold a significant portion of his holdings in the company. The transaction comes as the stock has shown remarkable momentum, surging 43% in the past week and maintaining an "Excellent" financial health score according to InvestingPro data. According to a regulatory filing, Molina sold 30,514 shares of common stock on March 13, 2025, at a weighted average price of $55.74 per share. This sale amounted to approximately $1.7 million. The transaction occurred with the stock trading near its 52-week high of $60.60, with technical indicators suggesting overbought conditions.
In addition to the sale, Molina exercised stock options to acquire 28,437 shares at $23.42 per share and 2,077 shares at $38.98 per share, with a combined total value of $746,956. Following these transactions, Molina retains ownership of 83,892 shares of Protagonist Therapeutics, representing a stake in the $3.37 billion market cap company. Analysts maintain a Strong Buy consensus on the stock, with detailed analysis available in the comprehensive Pro Research Report on InvestingPro.
In other recent news, Protagonist Therapeutics has reported significant developments in its clinical programs, leading to multiple analyst firms revising their price targets and maintaining positive ratings. BMO Capital Markets raised its price target to $72, citing promising data for Protagonist’s treatments for plaque psoriasis and ulcerative colitis. The firm expressed optimism about the potential of the oral IL-23 inhibitor, Icotrokinra, and maintained an Outperform rating. Similarly, Jefferies confirmed a Buy rating and a $68 target, following successful clinical trials for Icotrokinra in ulcerative colitis, noting its competitive efficacy compared to injectable treatments.
Truist Securities also adjusted its price target to $76, driven by positive Phase 2b trial results for rusfertide in ulcerative colitis, with a significant increase in projected peak sales. H.C. Wainwright maintained a Buy rating and a $54 target, highlighting the efficacy of Icotrokinra in psoriasis, with nearly half of the patients achieving completely clear skin. BTIG reaffirmed a Buy rating with a $73 target, expecting a significant increase in volume forecasts for the coming years, supported by strong order intake and new model launches. These recent updates reflect a strong confidence in Protagonist Therapeutics’ clinical progress and market potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.